Payment overview · 2025
General Payments
$2,775.98
155 reported records · 34 companies
Healthcare provider profile · identity verified
Paul S Moniz, DO
Allopathic & Osteopathic Physicians|Family Medicine · FARMINGTON, MO · NPI 1154373017
Verified facts
What the public records show
CMS Open Payments records show Paul S Moniz, DO received $2,775.98 in general payments during 2025 across 155 reported records.
ABBVIE INC. accounted for 18.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 53 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Caplyta, Creon, Eliquis, Farxiga, Gemtesa, Jardiance, Linzess, Mounjaro, Ozempic, Rexulti, Shingrix, Trintellix, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 165 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 306 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 1149 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 472 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 132 claims for Trelegy Ellipta by this doctor in 2024.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CAPLYTA as an associated drug or biological on 211855 records involving 46143 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Caplyta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Caplyta as an associated drug or biological on 11 records involving 9 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Caplyta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INVEGA SUSTENNA as an associated drug or biological on 39068 records involving 11966 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Invega Sustenna by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 365 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 306 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 212 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 122 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 2902 records involving 986 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Abilify Maintena by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 161 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Tresiba as an associated drug or biological on 415 records involving 264 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Tresiba by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 27924 records involving 10497 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Abilify Maintena by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Nuedexta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 1149 claims for Eliquis by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Lantus by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SOLIQUA 100/33 as an associated drug or biological on 43 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Soliqua 100-33 by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 119 claims for Gemtesa by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $511.97 | 18.4% | 34 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $266.09 | 9.6% | 13 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $213.86 | 7.7% | 12 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $184.90 | 6.7% | 12 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $152.70 | 5.5% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $141.41 | 5.1% | 11 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $113.86 | 4.1% | 5 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $113.61 | 4.1% | 8 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $111.95 | 4.0% | 6 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $94.92 | 3.4% | 4 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $88.77 | 3.2% | 4 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $87.49 | 3.1% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $82.25 | 3.0% | 4 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $63.54 | 2.3% | 3 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $55.85 | 2.0% | 3 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $55.69 | 2.0% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $50.50 | 1.8% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $44.42 | 1.6% | 2 | 2025 |
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $39.40 | 1.4% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $36.12 | 1.3% | 2 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $31.60 | 1.1% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $29.04 | 1.1% | 2 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $26.12 | 0.9% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $24.57 | 0.9% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $18.67 | 0.7% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $18.22 | 0.7% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $16.89 | 0.6% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $16.38 | 0.6% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$15.83 | 0.6% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $14.96 | 0.5% | 1 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$14.82 | 0.5% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $13.85 | 0.5% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $13.66 | 0.5% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $12.07 | 0.4% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,688.49 | 154 |
| Education | $87.49 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $296.11 | 16 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $266.09 | 13 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $179.57 | 16 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $171.08 | 8 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $162.14 | 10 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $152.70 | 6 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $150.74 | 8 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $115.35 | 8 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $113.86 | 5 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $113.86 | 5 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $113.61 | 8 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $111.95 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $101.85 | 8 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $94.92 | 4 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $88.77 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $63.58 | 3 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $63.54 | 3 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $55.69 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $50.75 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $39.56 | 3 | 2025 |
Source payment records
|
|||||
| TONMYA Normalized: tonmya |
Drug | Tonix Medicines, Inc. | $39.40 | 2 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $39.06 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $36.12 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $35.29 | 2 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $31.60 | 2 | 2025 |
Source payment records
|
|||||
| STRENSIQ Normalized: strensiq |
Biological | Alexion Pharmaceuticals, Inc. | $26.12 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $25.99 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $24.57 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $22.76 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $22.76 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $22.76 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $20.04 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $20.04 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $18.67 | 1 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $18.43 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $16.89 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $16.38 | 1 | 2025 |
Source payment records
|
|||||
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $15.83 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $15.21 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $14.96 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $14.96 | 1 | 2025 |
Source payment records
|
|||||
| ROTATEQ Normalized: rotateq |
Biological | Merck Sharp & Dohme LLC | $14.96 | 1 | 2025 |
Source payment records
|
|||||
| VAXELIS Normalized: vaxelis |
Biological | Merck Sharp & Dohme LLC | $14.96 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $14.96 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $14.88 | 1 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $14.82 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $14.16 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $13.85 | 1 | 2025 |
Source payment records
|
|||||
| PENMENVY Normalized: penmenvy |
Biological | GlaxoSmithKline, LLC. | $13.85 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $13.85 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $13.66 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $12.07 | 2 | 2025 |
Source payment records
|
|||||
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $10.65 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 98 | exact normalized | Medicare Part D |
| CAPLYTA caplyta |
2025 | Caplyta | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| CREON creon |
2025 | Creon | 2024 | 39 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 1149 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 165 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 119 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 306 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 66 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 212 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 161 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 38 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 472 | exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 91 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 77 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
66 | 16 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
57 | 17 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
77 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
165 | 31 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
44 | 16 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
306 | 43 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
1149 | 120 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
98 | 98 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
472 | 339 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
132 | 26 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) Exact reporting entity; no affiliate inference |
2025 | CAPLYTA open payments reported associated product |
CMS Open Payments — General Payments 211855 supporting records · 46143 recipient NPIs · example record 1241243071 |
Caplyta · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | Caplyta open payments reported associated product |
CMS Open Payments — General Payments 11 supporting records · 9 recipient NPIs · example record 1174547314 |
Caplyta · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | INVEGA SUSTENNA open payments reported associated product |
CMS Open Payments — General Payments 39068 supporting records · 11966 recipient NPIs · example record 1174223262 |
Invega Sustenna · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
365 | 35 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
306 | 43 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
212 | 34 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
122 | 25 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | ABILIFY MAINTENA open payments reported associated product |
CMS Open Payments — General Payments 2902 supporting records · 986 recipient NPIs · example record 1251759994 |
Abilify Maintena · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
161 | 32 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Tresiba open payments reported associated product |
CMS Open Payments — General Payments 415 supporting records · 264 recipient NPIs · example record 1188130328 |
Tresiba · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | ABILIFY MAINTENA open payments reported associated product |
CMS Open Payments — General Payments 27924 supporting records · 10497 recipient NPIs · example record 1227267721 |
Abilify Maintena · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
53 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
1149 | 120 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
84 | 24 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | SOLIQUA 100/33 open payments reported associated product |
CMS Open Payments — General Payments 43 supporting records · 15 recipient NPIs · example record 1233224976 |
Soliqua 100-33 · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
119 | 11 |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
91 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 2629 | 404 |
| Levothyroxine Sodium | Levothyroxine Sodium | 2091 | 295 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 1803 | 356 |
| Gabapentin | Gabapentin | 1626 | 259 |
| Furosemide | Furosemide | 1418 | 199 |
| Omeprazole | Omeprazole | 1377 | 230 |
| Pantoprazole Sodium | Pantoprazole Sodium | 1336 | 193 |
| Amlodipine Besylate | Amlodipine Besylate | 1281 | 215 |
| Potassium Chloride | Potassium Chloride | 1220 | 175 |
| Eliquis | Apixaban | 1149 | 120 |
| Lisinopril | Lisinopril | 1079 | 178 |
| Alprazolam | Alprazolam | 1015 | 188 |
| Tramadol Hcl | Tramadol Hcl | 951 | 201 |
| Metformin Hcl | Metformin Hcl | 941 | 161 |
| Montelukast Sodium | Montelukast Sodium | 901 | 166 |
| Trazodone Hcl | Trazodone Hcl | 867 | 143 |
| Duloxetine Hcl | Duloxetine Hcl | 825 | 132 |
| Prednisone | Prednisone | 794 | 435 |
| Tamsulosin Hcl | Tamsulosin Hcl | 789 | 132 |
| Metoprolol Tartrate | Metoprolol Tartrate | 723 | 116 |
| Buspirone Hcl | Buspirone Hcl | 721 | 116 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 721 | 136 |
| Metoprolol Succinate | Metoprolol Succinate | 701 | 115 |
| Carvedilol | Carvedilol | 689 | 101 |
| Famotidine | Famotidine | 632 | 101 |
| Losartan Potassium | Losartan Potassium | 597 | 106 |
| Sertraline Hcl | Sertraline Hcl | 595 | 84 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 589 | 93 |
| Mirtazapine | Mirtazapine | 569 | 80 |
| Clopidogrel | Clopidogrel Bisulfate | 564 | 87 |
| Lorazepam | Lorazepam | 508 | 111 |
| Spironolactone | Spironolactone | 492 | 67 |
| Donepezil Hcl | Donepezil Hcl | 473 | 66 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 472 | 339 |
| Allopurinol | Allopurinol | 462 | 80 |
| Baclofen | Baclofen | 440 | 72 |
| Fluoxetine Hcl | Fluoxetine Hcl | 435 | 70 |
| Ropinirole Hcl | Ropinirole Hcl | 428 | 61 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 425 | 34 |
| Escitalopram Oxalate | Escitalopram Oxalate | 422 | 70 |
| Myrbetriq | Mirabegron | 420 | 47 |
| Levetiracetam | Levetiracetam | 418 | 39 |
| Fluticasone Propionate | Fluticasone Propionate | 416 | 117 |
| Meloxicam | Meloxicam | 416 | 66 |
| Pravastatin Sodium | Pravastatin Sodium | 390 | 69 |
| Pregabalin | Pregabalin | 385 | 72 |
| Hydrochlorothiazide | Hydrochlorothiazide | 384 | 77 |
| Citalopram Hbr | Citalopram Hydrobromide | 365 | 69 |
| Xarelto | Rivaroxaban | 365 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 357 | 115 |
| Quetiapine Fumarate | Quetiapine Fumarate | 349 | 69 |
| Clonazepam | Clonazepam | 341 | 75 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 339 | 44 |
| Finasteride | Finasteride | 322 | 48 |
| Zolpidem Tartrate | Zolpidem Tartrate | 318 | 71 |
| Simvastatin | Simvastatin | 315 | 49 |
| Jardiance | Empagliflozin | 306 | 43 |
| Azithromycin | Azithromycin | 274 | 213 |
| Solifenacin Succinate | Solifenacin Succinate | 266 | 56 |
| Memantine Hcl | Memantine Hcl | 255 | 29 |
| Primidone | Primidone | 253 | 27 |
| Diazepam | Diazepam | 240 | 53 |
| Enalapril Maleate | Enalapril Maleate | 238 | 49 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 222 | 49 |
| Divalproex Sodium | Divalproex Sodium | 222 | 28 |
| Oxycodone Hcl | Oxycodone Hcl | 221 | 48 |
| Glipizide | Glipizide | 218 | 39 |
| Tizanidine Hcl | Tizanidine Hcl | 217 | 44 |
| Ezetimibe | Ezetimibe | 213 | 30 |
| Mounjaro | Tirzepatide | 212 | 34 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 211 | 28 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 209 | 50 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 202 | 28 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 185 | 31 |
| Topiramate | Topiramate | 179 | 24 |
| Lovastatin | Lovastatin | 178 | 28 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 174 | 23 |
| Celecoxib | Celecoxib | 173 | 28 |
| Hydralazine Hcl | Hydralazine Hcl | 171 | 43 |
| Warfarin Sodium | Warfarin Sodium | 168 | 22 |
| Amiodarone Hcl | Amiodarone Hcl | 167 | 28 |
| Bupropion Xl | Bupropion Hcl | 166 | 22 |
| Farxiga | Dapagliflozin Propanediol | 165 | 31 |
| Dicyclomine Hcl | Dicyclomine Hcl | 164 | 31 |
| Ozempic | Semaglutide | 161 | 32 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 158 | 38 |
| Bumetanide | Bumetanide | 158 | 21 |
| Januvia | Sitagliptin Phosphate | 156 | 26 |
| Aripiprazole | Aripiprazole | 147 | 19 |
| Latanoprost | Latanoprost | 147 | 27 |
| Nystatin | Nystatin | 147 | 67 |
| Amitriptyline Hcl | Amitriptyline Hcl | 140 | 26 |
| Colestipol Hcl | Colestipol Hcl | 140 | 30 |
| Clonidine Hcl | Clonidine Hcl | 139 | 28 |
| Ibuprofen | Ibuprofen | 138 | 29 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 136 | 36 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 135 | 98 |
| Doxycycline Hyclate | Doxycycline Hyclate | 133 | 111 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 132 | 26 |
| Olanzapine | Olanzapine | 131 | 22 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 131 | 54 |
| Temazepam | Temazepam | 130 | 22 |
| Midodrine Hcl | Midodrine Hcl | 125 | 18 |
| Testosterone Cypionate | Testosterone Cypionate | 124 | 25 |
| Benztropine Mesylate | Benztropine Mesylate | 123 | 13 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 123 | 122 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 122 | 21 |
| Ondansetron Hcl | Ondansetron Hcl | 122 | 57 |
| Trulicity | Dulaglutide | 122 | 25 |
| Gemtesa | Vibegron | 119 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 118 | 16 |
| Atenolol | Atenolol | 117 | 22 |
| Propranolol Hcl | Propranolol Hcl | 117 | 17 |
| Ondansetron Odt | Ondansetron | 116 | 49 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 116 | 19 |
| Metformin Hcl Er | Metformin Hcl | 115 | 25 |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 114 | 25 |
| Diclofenac Sodium | Diclofenac Sodium | 112 | 36 |
| Breo Ellipta | Fluticasone/Vilanterol | 106 | 19 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 106 | 86 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 106 | 25 |
| Oxybutynin Chloride | Oxybutynin Chloride | 106 | 15 |
| Cefdinir | Cefdinir | 103 | 90 |
| Irbesartan | Irbesartan | 102 | 16 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 98 | 98 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 93 | 17 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 92 | 19 |
| Trintellix | Vortioxetine Hydrobromide | 91 | suppressed |
| Westab Plus | Pnv,calcium 72/Iron/Folic Acid | 90 | suppressed |
| Digoxin | Digoxin | 89 | 12 |
| Venlafaxine Hcl | Venlafaxine Hcl | 89 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 86 | 14 |
| Lamotrigine | Lamotrigine | 85 | 14 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 84 | 24 |
| Pioglitazone Hcl | Pioglitazone Hcl | 84 | 12 |
| Metoclopramide Hcl | Metoclopramide Hcl | 82 | suppressed |
| Metolazone | Metolazone | 82 | 25 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 82 | 16 |
| Naproxen | Naproxen | 80 | 13 |
| Novolog Flexpen | Insulin Aspart | 80 | 17 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 77 | 61 |
| Cephalexin | Cephalexin | 77 | 47 |
| Vraylar | Cariprazine Hcl | 77 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 76 | 11 |
| Risperidone | Risperidone | 76 | 11 |
| Morphine Sulfate Er | Morphine Sulfate | 75 | 22 |
| Mupirocin | Mupirocin | 75 | 45 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 74 | 21 |
| Fluconazole | Fluconazole | 74 | 48 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 73 | 43 |
| M-Natal Plus | Pnv,calcium 72/Iron/Folic Acid | 73 | suppressed |
| Sucralfate | Sucralfate | 73 | 14 |
| Doxazosin Mesylate | Doxazosin Mesylate | 71 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 70 | suppressed |
| Glimepiride | Glimepiride | 70 | 21 |
| Lactulose | Lactulose | 70 | 20 |
| Alendronate Sodium | Alendronate Sodium | 69 | 19 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 69 | 40 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 67 | 21 |
| Divalproex Sodium Er | Divalproex Sodium | 66 | 11 |
| Linzess | Linaclotide | 66 | 16 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 64 | 11 |
| Namzaric | Memantine Hcl/Donepezil Hcl | 63 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 63 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 63 | 16 |
| Meclizine Hcl | Meclizine Hcl | 62 | 19 |
| Eszopiclone | Eszopiclone | 61 | suppressed |
| Nitroglycerin | Nitroglycerin | 61 | 25 |
| Fenofibrate | Fenofibrate | 60 | 14 |
| Prazosin Hcl | Prazosin Hcl | 59 | suppressed |
| Calcitriol | Calcitriol | 58 | 11 |
| Synthroid | Levothyroxine Sodium | 57 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 54 | 14 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 53 | 12 |
| Glipizide Er | Glipizide | 53 | 13 |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 53 | suppressed |
| Carbamazepine | Carbamazepine | 52 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 50 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 50 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 50 | 24 |
| Sumatriptan Succinate | Sumatriptan Succinate | 50 | 12 |
| Humalog Kwikpen U-100 | Insulin Lispro | 49 | 15 |
| Methotrexate | Methotrexate Sodium | 49 | suppressed |
| Entresto | Sacubitril/Valsartan | 47 | 13 |
| Ketoconazole | Ketoconazole | 47 | 31 |
| Lansoprazole | Lansoprazole | 47 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 46 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 46 | 11 |
| Tradjenta | Linagliptin | 46 | suppressed |
| Estradiol | Estradiol | 45 | 11 |
| Loperamide | Loperamide Hcl | 45 | 24 |
| Advair Hfa | Fluticasone Propion/Salmeterol | 44 | 12 |
| Cilostazol | Cilostazol | 44 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 44 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 44 | 16 |
| Diltiazem 24hr Er | Diltiazem Hcl | 43 | suppressed |
| Nystop | Nystatin | 43 | 22 |
| Nebivolol Hcl | Nebivolol Hcl | 42 | suppressed |
| Ranolazine Er | Ranolazine | 42 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 42 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 41 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 40 | 16 |
| Methocarbamol | Methocarbamol | 40 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 40 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 39 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 39 | 11 |
| Creon | Lipase/Protease/Amylase | 39 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 39 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 39 | 12 |
| Valacyclovir | Valacyclovir Hcl | 39 | 12 |
| Rexulti | Brexpiprazole | 38 | suppressed |
| Techlite Pen Needle | Pen Needle, Diabetic | 38 | 15 |
| Vilazodone Hcl | Vilazodone Hcl | 38 | suppressed |
| Budesonide | Budesonide | 37 | suppressed |
| Carisoprodol | Carisoprodol | 37 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 36 | suppressed |
| Brilinta | Ticagrelor | 36 | suppressed |
| Caplyta | Lumateperone Tosylate | 36 | suppressed |
| Haloperidol | Haloperidol | 36 | suppressed |
| Cyclosporine | Cyclosporine | 35 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 35 | suppressed |
| Ramipril | Ramipril | 35 | suppressed |
| Vascepa | Icosapent Ethyl | 35 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 34 | suppressed |
| Fentanyl | Fentanyl | 34 | 12 |
| Liothyronine Sodium | Liothyronine Sodium | 34 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 34 | 12 |
| Varenicline Tartrate | Varenicline Tartrate | 33 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 32 | suppressed |
| Novofine Autocover | Pen Needle, Diabetic, Safety | 32 | suppressed |
| Ramelteon | Ramelteon | 32 | suppressed |
| Repatha Sureclick | Evolocumab | 32 | suppressed |
| Timolol Maleate | Timolol Maleate | 32 | suppressed |
| Cartia Xt | Diltiazem Hcl | 31 | suppressed |
| Torsemide | Torsemide | 31 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 30 | suppressed |
| Hydrocortisone | Hydrocortisone | 30 | 16 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 30 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 30 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 29 | 25 |
| Flecainide Acetate | Flecainide Acetate | 29 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 29 | suppressed |
| Verapamil Er | Verapamil Hcl | 29 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 28 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 28 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 28 | 11 |
| Hydromorphone Hcl | Hydromorphone Hcl | 28 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 28 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 28 | 14 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Levofloxacin | Levofloxacin | 27 | 20 |
| Spiriva Handihaler | Tiotropium Bromide | 27 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 26 | 11 |
| Brimonidine Tartrate | Brimonidine Tartrate | 26 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 26 | suppressed |
| Movantik | Naloxegol Oxalate | 26 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 26 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 26 | suppressed |
| Amoxicillin | Amoxicillin | 25 | 17 |
| Chlorthalidone | Chlorthalidone | 25 | 11 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 25 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 25 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 25 | suppressed |
| Paliperidone Er | Paliperidone | 25 | suppressed |
| Acyclovir | Acyclovir | 24 | 13 |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 24 | suppressed |
| Carbamazepine Er | Carbamazepine | 24 | suppressed |
| Lidocaine | Lidocaine | 23 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 22 | suppressed |
| Dalfampridine Er | Dalfampridine | 22 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 22 | suppressed |
| Modafinil | Modafinil | 22 | suppressed |
| Phenytoin | Phenytoin | 22 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 22 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 22 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 21 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 21 | suppressed |
| Droxidopa | Droxidopa | 21 | suppressed |
| Leflunomide | Leflunomide | 21 | suppressed |
| Sotalol | Sotalol Hcl | 21 | suppressed |
| Belsomra | Suvorexant | 20 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Humalog Mix 75-25 | Insulin Lispro Protamin/Lispro | 20 | suppressed |
| Nyamyc | Nystatin | 20 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 20 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 20 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 19 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 19 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 19 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 19 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 19 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 18 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 18 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 18 | suppressed |
| Enalapril-Hydrochlorothiazide | Enalapril/Hydrochlorothiazide | 18 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 18 | suppressed |
| Humalog | Insulin Lispro | 18 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 18 | suppressed |
| Lacosamide | Lacosamide | 18 | suppressed |
| Levemir Flexpen | Insulin Detemir | 18 | suppressed |
| Methimazole | Methimazole | 18 | suppressed |
| Novolog | Insulin Aspart | 18 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 18 | suppressed |
| Rivastigmine | Rivastigmine | 18 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 18 | suppressed |
| Telmisartan | Telmisartan | 18 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 18 | suppressed |
| Colchicine | Colchicine | 17 | suppressed |
| Folic Acid | Folic Acid | 17 | suppressed |
| Mirabegron Er | Mirabegron | 17 | 11 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 17 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 17 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 16 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 16 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 16 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 15 | 15 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 15 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Metronidazole | Metronidazole | 15 | 12 |
| Naltrexone Hcl | Naltrexone Hcl | 15 | suppressed |
| Roflumilast | Roflumilast | 15 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 15 | suppressed |
| Trospium Chloride | Trospium Chloride | 15 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 15 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 14 | suppressed |
| Constulose | Lactulose | 14 | suppressed |
| Entacapone | Entacapone | 14 | suppressed |
| Epinephrine | Epinephrine | 14 | 11 |
| Icosapent Ethyl | Icosapent Ethyl | 14 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 14 | suppressed |
| Polymyxin B Sul-Trimethoprim | Polymyxin B Sulf/Trimethoprim | 14 | 12 |
| Prednisolone Acetate | Prednisolone Acetate | 14 | suppressed |
| Rhopressa | Netarsudil Mesylate | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 14 | suppressed |
| Abilify Maintena | Aripiprazole | 13 | suppressed |
| Anastrozole | Anastrozole | 13 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 13 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 13 | suppressed |
| Pentips Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Triazolam | Triazolam | 13 | suppressed |
| Zonisamide | Zonisamide | 13 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 12 | suppressed |
| Budesonide Dr | Budesonide | 12 | suppressed |
| Clozapine Odt | Clozapine | 12 | suppressed |
| Ethosuximide | Ethosuximide | 12 | suppressed |
| Insulin Lispro | Insulin Lispro | 12 | suppressed |
| Levoxyl | Levothyroxine Sodium | 12 | suppressed |
| Lumigan | Bimatoprost | 12 | suppressed |
| Phenytek | Phenytoin Sodium Extended | 12 | suppressed |
| Saxagliptin Hcl | Saxagliptin Hcl | 12 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 12 | suppressed |
| Travoprost | Travoprost | 12 | suppressed |
| Tresiba | Insulin Degludec | 12 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 11 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 11 | suppressed |
| Calcium Acetate | Calcium Acetate | 11 | suppressed |
| Clotrimazole | Clotrimazole | 11 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 11 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 11 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 11 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 11 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 11 | suppressed |
| Restasis | Cyclosporine | 11 | suppressed |
| Testosterone | Testosterone | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,775.98 · 155 records | ABBVIE INC. | ABRYSVO, AREXVY, Auvelity, BREZTRI, CAPLYTA, CAPVAXIVE, COBENFY, COMIRNATY, CREON, Cologuard Collection Kit, ELIQUIS, FANAPT, FARXIGA, GARDASIL 9, GEMTESA, INCEPTIV, INGREZZA, JARDIANCE, Kerendia, Korlym, LINZESS, MAVYRET, MOUNJARO, NURTEC ODT, Ohtuvayre, Ozempic, PENMENVY, PREVNAR 20, QULIPTA, REXULTI, ROTATEQ, Rybelsus, SHINGRIX, SPRAVATO, STRENSIQ, Senza, Sunosi, TONMYA, TRINTELLIX, TZIELD, The Cologuard Plus Collection Kit, UBRELVY, VALTOCO, VAXELIS, VAXNEUVANCE, VOQUEZNA, VRAYLAR, Wegovy, XIFAXAN, YUPELRI, ZAVZPRET, ZENPEP, ZEPBOUND | 32 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error